ALX Oncology Holdings Inc at JPMorgan Healthcare Conference Transcript
Hi, everyone. Welcome. It's a great to have everyone back in person. My name is (inaudible). I'm an associate here in the healthcare investment banking team. It's my absolute pleasure to introduce Jaume Pons, CEO and President of ALX Oncology.
Thank you. So after the customary disclaimers, let's move to CD47 as a target and Evorpacept our clinical candidate as a CD47 blocker.
So here on the left, you have the expression of CD47 in cancer cells in red and normal cells in black. As you can see, CD47 is very highly overexpressed in tumors, but also is like highly expressed in normal tissues. Therefore, if you want to use CD47 as a tumor target and kill all CD47 positive cells, you will be producing a lot of toxicity. Quite interesting to us about CD47 is its function as a myeloid checkpoint.
So it functions very similarly to PD-1, PD-L1, but instead of these cells, we are here talking about macrophages and dendritic cells in the innate immune
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
